Protein RAMP3 Changes How GLP-1 Receptors Work, Potentially Reducing Side Effects
RAMP3 modifies the GLP-1 receptor to bias signaling toward calcium mobilization and enhanced insulin secretion, potentially enabling more targeted GLP-1 drugs with fewer side effects.
Quick Facts
What This Study Found
RAMP3 interacts with the GLP-1 receptor, biasing signaling toward Ca2+ mobilization (away from cAMP), which enhanced glucose-stimulated insulin secretion in pancreatic cells.
Key Numbers
RAMP3 reduced Gαs coupling, increased Gαq and Gαi coupling. Shifted signaling from cAMP to Ca2+ mobilization. Enhanced glucose-stimulated insulin secretion in RAMP3-overexpressing cells.
How They Did This
Cell-based laboratory study examining RAMP3-GLP-1 receptor interaction, signaling bias, surface expression, and functional effects on insulin secretion.
Why This Research Matters
Current GLP-1 drugs activate the receptor the same way everywhere in the body, causing side effects. RAMP3 shows a way to achieve tissue-selective signaling that could lead to better-tolerated medications.
The Bigger Picture
RAMPs represent a new frontier in GPCR drug design. By understanding how these accessory proteins modify receptor signaling, scientists could develop next-generation GLP-1 drugs with improved tissue selectivity and safety profiles.
What This Study Doesn't Tell Us
Cell-based study — the RAMP3 effects on GLP-1 signaling have not been confirmed in animal models or humans. The therapeutic potential is theoretical at this stage.
Questions This Raises
- ?Can RAMP3-selective GLP-1 agonists be designed that retain metabolic benefits while avoiding GI side effects?
- ?How does RAMP3 expression vary across different tissues and disease states?
Trust & Context
- Key Stat:
- Signaling bias toward Ca2+ RAMP3 shifted GLP-1 receptor signaling from cAMP toward calcium mobilization, enhancing insulin secretion in pancreatic beta cells
- Evidence Grade:
- In vitro cell-based study providing mechanistic insight. Strong for understanding receptor biology but requires in vivo validation before therapeutic implications can be confirmed.
- Study Age:
- Published in 2025, representing cutting-edge receptor pharmacology research with implications for next-generation GLP-1 drug design.
- Original Title:
- Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion.
- Published In:
- The Journal of biological chemistry, 301(10), 110604 (2025)
- Authors:
- Pearce, Abigail(2), Kumari, Poonam(2), Sisk, Claudia M(2), Harris, Matthew, Yeung, Ho Yan, Winfield, Sabrina, Caron, Kathleen M, Ladds, Graham
- Database ID:
- RPEP-12995
Evidence Hierarchy
Frequently Asked Questions
What are RAMPs and why do they matter for GLP-1 drugs?
RAMPs (receptor activity-modifying proteins) are accessory proteins that physically pair with receptors and change how they behave. RAMP3 modifies the GLP-1 receptor to signal differently, which could enable development of drugs that activate the receptor in some tissues but not others — potentially keeping the diabetes benefits while reducing gut side effects.
Could this lead to GLP-1 drugs without nausea?
Potentially. If future drugs can be designed to specifically target RAMP3-modified GLP-1 receptors in the pancreas while avoiding gut receptors, they might enhance insulin secretion with fewer gastrointestinal side effects. This is still theoretical and requires extensive research.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12995APA
Pearce, Abigail; Kumari, Poonam; Sisk, Claudia M; Harris, Matthew; Yeung, Ho Yan; Winfield, Sabrina; Caron, Kathleen M; Ladds, Graham. (2025). Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion.. The Journal of biological chemistry, 301(10), 110604. https://doi.org/10.1016/j.jbc.2025.110604
MLA
Pearce, Abigail, et al. "Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion.." The Journal of biological chemistry, 2025. https://doi.org/10.1016/j.jbc.2025.110604
RethinkPeptides
RethinkPeptides Research Database. "Receptor activity-modifying protein 3 enhances GLP-1-mediate..." RPEP-12995. Retrieved from https://rethinkpeptides.com/research/pearce-2025-receptor-activitymodifying-protein-3
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.